rimantadine

REMS

Prevention and treatment of influenza A infection in high-risk adults.
Prevention of influenza A infection in high-risk children.

Unlabeled Use:

Treatment of influenza A infection in children.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Hypersensitivity to rimantadine or amantadine;
Lactation: Lactation.

Use Cautiously in:

History of seizures;
Severe renal impairment (dose ↓ recommended if CCr <30 mL/min);
Severe hepatic impairment;
OB: Safety not established in pregnancy;
Geri: Older adults may be at ↑ risk for GI effects.

Adv. Reactions/Side Effects ⬆ ⬇

Derm: rash

EENT: tinnitus

GI: abdominal pain, anorexia, diarrhea, dry mouth, dyspepsia, nausea, vomiting

Neuro: agitation, depression, dizziness, fatigue, headache, impaired concentration, insomnia, SEIZURES

Resp: dyspnea

Interactions ⬆ ⬇

Drug-drug:

Aspirin and acetaminophen may ↓ levels and effectiveness.
May interfere with efficacy of intranasal influenza virus vaccine; do not administer within 48 hr before or 2 wk after.

Availability ⬆ ⬇

(Generic available)

Tablets: 100 mg

Route/Dosage ⬆ ⬇

PO (Adults ): Prevention: 100 mg twice daily (duration range = 11 days-6 wk). Treatment: 100 mg twice daily for 7 days.
PO Geriatric Patients ): Prevention: 100 mg daily.
PO (Children 10–16 yr): Prevention: 100 mg twice daily (duration range = 5–6 wk).
PO (Children 1–9 yr): Prevention: 5 mg/kg/day as a single dose (not to exceed 150 mg/day) (duration range = 5–6 wk).

Renal Impairment

PO (Adults ): Severe renal impairment: Prevention: 100 mg daily.

Hepatic Impairment

PO (Adults ): Severe hepatic impairment: Prevention: 100 mg daily.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Diminishes replication of influenza A virus by inhibiting uncoating of the virus.

Therapeutic effects:

When given prophylactically, prevents infection with influenza A virus. When administered within 48 hr of onset of infections, decreases the duration of fever and other associated symptoms.

Classifications ⬆ ⬇

Therapeutic Classification: antivirals

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed after oral administration.

Distribution: Unknown.

Metabolism/Excretion: Mostly metabolized by the liver; <25% excreted unchanged in urine.

Half-Life: 25 hr (range 13–65 hr).

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
PO	rapid	6 hr	N/A

Patient/Family Teaching ⬆ ⬇

Explain purpose and side effects of medication to patient. Advise patient to read Patient Information before starting therapy. Advise patient to take as directed at evenly spaced times for full course of therapy, even if feeling well. Take missed doses as soon as possible unless almost time for next dose; do not double up on missed doses.
Advise patient to consult health care professional before taking OTC medications or herbal products, especially aspirin or acetaminophen, or drinking alcoholic beverages.
May cause dizziness. Advise patient to avoid driving or other activities that require alertness until response to the drug is known.
Advise patient to consult health care professional about receiving a flu vaccination.
Inform patient that frequent mouth rinses, good oral hygiene, and sugarless gum or candy may ↓ dry mouth.
Instruct patient and family to notify health care professional if influenza symptoms occur.
Rep: Advise women of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1911- Rimantadine Hydrochloride
  - 0115-1911-01- 100 TABLET, FILM COATED in 1 BOTTLE (0115-1911-01)

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1911- Rimantadine Hydrochloride
  - 0115-1911-02- 500 TABLET, FILM COATED in 1 BOTTLE (0115-1911-02)

63818- Olpha AS
- 63818-0434-
  - 63818-0434-3- 20 kg in 1 CONTAINER (63818-0434-3)

63818- Olpha AS
- 63818-0434-
  - 63818-0434-4- 25 kg in 1 CONTAINER (63818-0434-4)

section name header

Indications ⬇